We present a case of cerebellar dysfunction due to severe hypothyroidism induced by pembrolizumab, a member of the ‘immune checkpoint inhibitor’ class of cancer immunotherapies. Thyroxine replacement completely resolved his symptoms and signs. We also discuss the neurological immune-related complications of checkpoint inhibitors.
- cerebellar ataxia
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Contributors AB drafted this case report. CM and AJC edited the report and contributed to the discussion.
Competing interests None declared.
Patient consent Obtained.
Provenance and peer review Not commissioned; externally peer reviewed. This paper was reviewed by Marios Hadjivassiliou, Sheffield, UK.
Correction notice This article has been corrected since it was published Online First. The affiliations numbered 2 and 3 have been switched around.
Read the full text or download the PDF:
Other content recommended for you
- Checkpoint inhibitors in head and neck cancer: current knowledge and perspectives
- Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events
- Immune checkpoint inhibitor-induced hypophysitis: lessons learnt from a large cancer cohort
- Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience
- Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
- Cardiotoxicity of immune checkpoint inhibitors
- Investigating hypothyroidism
- Autoimmune complications of immunotherapy: pathophysiology and management
- Central nervous system complications associated with immune checkpoint inhibitors